Navigation Links
Omeros Announces Clinical Development Programs for OMS103HP and OMS302
Date:5/19/2011

SEATTLE, May 19, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it is advancing two of its product candidates from its PharmacoSurgery™ platform – OMS103HP for arthroscopic meniscectomy and OMS302 for intra-ocular lens replacement surgery – into Phase 3 clinical development programs. Both of these product candidates are added to standard irrigation solutions and delivered intra-operatively to the operative site throughout the surgical procedure to preemptively block the molecular-signaling and biochemical cascade caused by surgical trauma and to provide clinical benefits both during and after surgery.

"I am pleased to report today that we have already begun advancing Phase 3 clinical programs for OMS103HP and OMS302," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.  "Both of these drugs generated positive efficacy and safety data in large Phase 2 clinical trials and, based on our analysis of those data, we are optimistic that each drug's clinical benefits will be further demonstrated in its respective Phase 3 clinical program."

The OMS103HP Phase 3 clinical program will evaluate the drug's safety and efficacy in improving postoperative joint function and reducing pain following arthroscopic partial meniscectomy surgery. The program will consist of two randomized, double-blind, vehicle-controlled, multicenter trials to be conducted in North America and Europe. Omeros expects data from the North American trial in the first half of 2012. The Company is in discussions with European regulatory authorities regarding the second clinical trial and, assuming sufficient resources, plans to begin that trial during the fourth quarter of 2011. The primary endpoint for these trials will be performance on the Knee Injury and Osteoarthritis Outcome Score (KOOS), a validated patient-reported o
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Corporation Reports First Quarter 2011 Financial Results
2. Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
3. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
4. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
5. Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
6. Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
7. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
8. Omeros Announces Publication of Data From Antifibrinolytic Program
9. Omeros Licenses Novel Antifibrinolytic Agents
10. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
11. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  CryoLife, Inc. (NYSE: CRY ), a ... cardiac and vascular surgery, announced today that James ... has been elected to the Company,s Board of Directors, ... Anderson , Executive Chairman of CryoLife, stated, "Since joining the ... excellent leader who is well positioned to maximize CryoLife,s ...
(Date:10/22/2014)... , Oct. 21, 2014  Early symptoms ... subtle or unnoticed, but new technology, coupled with ... and leading to earlier detection of eye diseases, ... 29 million Americans. If left untreated, these diseases ... blindness. Recently, optometric researchers have ...
(Date:10/22/2014)... Mass. , Oct. 22, 2014 InVivo ... Cambridge, MA is revolutionizing spinal cord injury ... has been shown to outperform in tissue regrowth in ... the scaffold.  Made from an FDA approved polymer, the ... making it harmless to the human body. NVIV has ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... approved Makena (hydroxyprogesterone caproate) in February 2011 for the ... women who have had at least one prior preterm ... version of the active ingredient of Makena has been ... a pharmacist who compounded the drug.  In March 2011, ...
... Covance Inc. (NYSE: CVD ) today announced ... on Thursday, November 10, 2011 at 3:00 p.m. (ET).  Investors ... www.covance.com .  In order to register and download any necessary ... with headquarters in Princeton, New Jersey, is one of the ...
Cached Medicine Technology:FDA Statement on Makena 2Covance to Present at Credit Suisse 2011 Healthcare Conference 2
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world ... face, it certainly can be difficult to choose the right ... favor by doing it the healthy way? Set aside the ... your body, exercise regularly, and choose foods with the most ... you need to exercise more and eat less. Despite the ...
(Date:10/22/2014)... 22, 2014 Lintelus, Inc., an event ... President of Sales, will be speaking on the subject ... Expo on October 28, at the Holiday Inn in ... booth as well as a Tech Demo at 12:45pm, ... create a more engaging event experience. , The Annual ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter , ... in vitro fertilization (IVF) are only about half as likely ... reproduction technique, new research indicates, and the racial disparity persists ... about 31 percent of white patients became pregnant after IVF, ... more than 4,000 IVF cycles over two years to tease ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... may lead to increased blood pressure, according to a new ... in blood pressure for young adult women or for teenagers, ... drank lightly or moderately, their risk of high blood pressure ... parallels studies in older adult men and women," said lead ...
Breaking Medicine News(10 mins):Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... of abuse by intimate partners have significantly higher health ... of such abuse, according to a study conducted at ... higher costs and utilization continued long after the abuse ... of Washington (UW), and the Harborview Injury Prevention and ...
... how some passengers describe it.// , They ... were infected with a stomach flu-causing bug; norovirus aboard the ... This virus causes a contagious gastric illness, gastroenteritis that leaves ... , The liner’s owner Cunard Line notified the ...
... that neurologists believe will help in the management of epilepsy. ... New York carried out a study that showed that some ... occur. The findings were published in Neurology, the scientific journal ... Haut. ,Haut's team studied 71 adult patients ...
... and Forests has called for an action plan and ... National Workshop// on ‘Human - Leopard Conflict Management’ here ... need to have a re-look at our existing strategies ... one of the challenging issues facing wildlife managers in ...
... Parliament's health committee is all set to tighten the ... ,Three days of public hearing starting on Jan 23, ... organizations will make submissions before the committee. ... and the sponsorship of sports and other popular events ...
... (VBI) Assistant Professor Biswarup Mukhopadhyay has provided important ... diabetics in the// December 22, 2006, Journal of ... time help researchers to identify potential targets for ... fully eliminate, the body's overproduction of glucose. ...
Cached Medicine News:Health News:Health Care Costs - Significant for Abused Women 2Health News:When Epilepsy Patients Play Soothsayers 2Health News:VBI Provides Potential Targets to Diabetes Therapeutics 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: